Hyperuricemia ≠ Gout! How to prevent and control this hidden health killer—Teijin Gout (Febuxostat) becomes a key weapon in uric acid management.
Share
A medical checkup report showed uric acid at 520 μmol/L, but I've never had joint pain—do I need treatment? Medical truth: Only 10% of patients with hyperuricemia will develop gout , but the remaining 90% still face the risk of heart and kidney failure! This article provides an in-depth analysis of the differences between the two and reveals the scientific value of the original drug Teijin Gout (febuxostat) in the comprehensive management of uric acid.
I. Hyperuricemia ≠ Gout: Three Core Differences
▶ Difference 1: Different nature of the disease
|
index |
hyperuricemia |
gout |
|
definition |
Serum uric acid > 420 μmol/L (male) |
Arthritis caused by urate crystal deposition |
|
symptom |
90% asymptomatic |
Severe joint pain/redness/limited range of motion |
|
Diagnostic basis |
Biochemical test results |
Clinical symptoms + uric acid levels + imaging evidence |
▶ Difference 2: Different scope of harm
● Hyperuricemia : Silent damage to the whole body
○ Kidneys : Uric acid crystals → kidney stones/interstitial fibrosis (eGFR decreases by 1.2% annually)
○ Vascular : Oxidative stress → Arteriosclerosis (23% increased risk of coronary heart disease)
Metabolism : Insulin resistance → Increased risk of diabetes by 25%
● Gout : primarily affects the joints.
○ Recurrent attacks lead to bone erosion and joint deformities
▶ Difference 3: Different timing of intervention
● Hyperuricemia : uric acid > 540 μmol/L Initiate drug treatment immediately
● Gout :
○ Acute phase: Anti-inflammatory and analgesic (colchicine/NSAIDs)
○ Remission phase: Uric acid-lowering therapy (target value <360 μmol/L)
Key finding : Even without a gout attack, individuals with uric acid levels >540 μmol/L have a 40% or higher risk of kidney damage within 5 years !
II. Why is uric acid control the core issue ? Three scientific principles
1. Preventing acute gout attacks
When serum uric acid is >600 μmol/L, the annual incidence of gout is as high as 30.5% ; controlling it to <360 μmol/L can reduce the frequency of attacks by 80% .
2. Blocking progressive damage to the heart and kidneys
● Kidney protection : For every 60 μmol/L reduction in uric acid, the risk of chronic kidney disease progression decreases by 14%.
● Cardiovascular benefits : Maintaining uric acid levels <360 μmol/L reduces heart failure hospitalization rates by 27%.
3. Reversing tissue deposition lesions
Sustained target level (<300 μmol/L) treatment for 2 years:
● Gout tophi shrank by 62%
● The dissolution rate of urate crystals in joints is increased by 3.8 times.
III. Teijin Gout Treatment (Febuxostat): A "Precise Regulator" for Uric Acid Management
▶ Advantages of the original drug: the culmination of 40 years of research and development by Teijin, Japan
● Precise target targeting : Selectively inhibits xanthine oxidase (XO), with a potency 1000 times greater than allopurinol.
● Dual excretion pathway : 49% renal excretion + 45% fecal excretion. No dose reduction is required for patients with mild to moderate renal impairment (eGFR ≥ 30 mL/min).
▶ Clinical value: Full-cycle management from intervention to maintenance
|
Treatment phase |
febuxostat core function |
Evidence-based evidence |
|
Rapid acid reduction |
Treatment with 40mg for 2 weeks achieved a target concentration (<360μmol/L) rate of 58%. |
Asia Pacific CONFIRMS Trial |
|
Long-term maintenance |
The recurrence rate of gout after 3 years of medication is < 5%. |
Japan EXTEND Study |
|
Special populations |
Zero reports of allergies among HLA-B*5801 positive individuals in Asia. |
Real World Research in China |
IV. Scientific Medication Strategies: Avoiding Misconceptions and Optimizing Efficacy
1. Personalized starting dose (strictly follow doctor's orders)
● No cardiovascular disease: Start with 40mg/day
● Combined with ischemic heart disease: Start with 20mg/day → titrate gradually
2 . Avoid two major risks
● Metastatic relapse : Initially, colchicine (0.5 mg/day) should be used in combination for 3-6 months.
● Liver function monitoring : ALT levels should be tested monthly for the first 3 months before starting medication.
V. Closed-loop management throughout the entire process: medication + lifestyle + monitoring
1. Drug therapy is the cornerstone
● The original febuxostat is available in all strengths: 10mg, 20mg, and 40mg , with support for fine-tuning.
2. Lifestyle intervention
● Drink water : ≥2000ml per day (reduces the risk of kidney stones by 37%)
● Diet : Limit red meat/seafood/fructose (can lower uric acid by 10-15% )
3. Dynamic monitoring network
● Monthly uric acid testing
● Four-quarter liver and kidney function
● Annual echocardiogram/carotid ultrasound
Hyperuricemia is a "metabolic time bomb" hidden in the body, with harm far exceeding joint pain. Teijin Gout (Febuxostat) has become the core choice for comprehensive uric acid management due to its three major advantages: potent uric acid lowering, kidney-friendly formula, and flexible dosage . Remember: Controlling uric acid is protecting your heart and kidneys!
🏆 Asakusa Cosmetics provides you with
✔️ Authentic Febuxostat
✔️ Hospital prescription
✔️ Online doctor consultation
✔️ Pharmacist's Medication Instructions
✔️ Comprehensive after-sales tracking service
⚠️ Friendly reminder: This article is for reference only. Please consult your doctor for specific medication advice.
---------------------------------------------------------------------------------------------------
📞Welcome to scroll down to contact customer service, purchase online, and have it shipped directly to your door.